Endostatin is a broad spectrum angiogenesis inhibitor and may interfere with the pro-angiogenic action of growth factors such as basic fibroblast growth factor (bFGF/FGF-2) and vascular endothelial growth factor (VEGF).
Endostatin is currently being studied as part of cancer research.
In a Phase I clinical trial of Endostatin of the 19 patients treated, 12 were switched out of the trial by their physicians due to continued progression of their disease.
Two patients continued to be treated, and the remaining patients withdrew on their own.
The trial, designed primarily to demonstrate safety, indeed showed that the drug was safe and well-tolerated.
In a Phase II clinical trial of Endostatin forty two patients with pancreatic endocrine tumors or carcinoid tumors were treated. Of the 40 patients which could be evaluated for a radiologic response, none experienced partial response to therapy, as defined by World Health Organization criteria.
The conclusion from the trial was that "Treatment with Endostatin did not result in significant tumor regression in patients with advanced neuroendocrine tumors."
- Folkman, J. (2006). "Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action". Exp. Cell. Res. 312: 594–607. Unknown parameter
- "Boston hospitals report early results of Endostatin clinical trial" (Press release). Dana-Farber Cancer Institute. November 2000. Retrieved 2006-07-12.
- Kulke M H; et al. (2006). "Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors". J. Clin. Oncol. 24: 3555–3561. Unknown parameter
- Endostatin at the US National Library of Medicine Medical Subject Headings (MeSH)
- PBS' Nova program explores Endostatin in 2001
|40px||This biochemistry article is a stub. You can help Wikipedia by expanding it.|